MC1550A1 - Forme de dosage orale - Google Patents

Forme de dosage orale

Info

Publication number
MC1550A1
MC1550A1 MC831659A MC1659A MC1550A1 MC 1550 A1 MC1550 A1 MC 1550A1 MC 831659 A MC831659 A MC 831659A MC 1659 A MC1659 A MC 1659A MC 1550 A1 MC1550 A1 MC 1550A1
Authority
MC
Monaco
Prior art keywords
dosage form
oral dosage
oral
dosage
Prior art date
Application number
MC831659A
Other languages
English (en)
Inventor
Charanjit Behl
George Beskid
Navnit Shah
Jacques Tossounian
Joel Unowsky
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MC1550A1 publication Critical patent/MC1550A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MC831659A 1982-10-15 1983-10-14 Forme de dosage orale MC1550A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/434,452 US4525339A (en) 1982-10-15 1982-10-15 Enteric coated oral dosage form

Publications (1)

Publication Number Publication Date
MC1550A1 true MC1550A1 (fr) 1984-08-31

Family

ID=23724297

Family Applications (1)

Application Number Title Priority Date Filing Date
MC831659A MC1550A1 (fr) 1982-10-15 1983-10-14 Forme de dosage orale

Country Status (14)

Country Link
US (1) US4525339A (fr)
EP (1) EP0108295A1 (fr)
JP (1) JPS59104312A (fr)
KR (1) KR840006437A (fr)
AU (1) AU2019283A (fr)
DK (1) DK473183A (fr)
FI (1) FI833728A (fr)
GR (1) GR82301B (fr)
IL (1) IL69960A0 (fr)
MC (1) MC1550A1 (fr)
NO (1) NO833757L (fr)
PT (1) PT77503A (fr)
ZA (1) ZA837307B (fr)
ZW (1) ZW22183A1 (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60146825A (ja) * 1984-01-10 1985-08-02 Asahi Chem Ind Co Ltd 経口医薬製剤
CA1256799A (fr) * 1984-02-22 1989-07-04 Walter Fuller Suppositoires
US4760059A (en) * 1985-08-05 1988-07-26 Hoffmann-La Roche Inc. Rectal dosage form
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
DE3887179T2 (de) * 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
KR880012221A (ko) * 1987-04-13 1988-11-26 사노 가즈오 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
IE59934B1 (en) * 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
DE3729299A1 (de) * 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
US5009894A (en) * 1988-03-07 1991-04-23 Baker Cummins Pharmaceuticals, Inc. Arrangement for and method of administering a pharmaceutical preparation
US5260271A (en) * 1988-06-22 1993-11-09 Applied Microbiology, Inc. Nisin compositions for use as enhanced broad range bactericides
US4925674A (en) * 1988-08-25 1990-05-15 Himedics, Inc. Amoxicillin microencapsulated granules
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
ZA898331B (en) * 1988-11-22 1990-07-25 Hoffmann La Roche Pharmaceutical compositions
ZA906186B (en) * 1989-09-11 1991-06-26 Hoffmann La Roche Pharmaceutical preparations
US6482516B1 (en) * 1993-07-20 2002-11-19 Banner Pharmacaps, Inc. Enrobed tablet
AT393955B (de) * 1990-03-30 1992-01-10 Martin Dr Leixnering Einrichtung zur nachbehandlung frischer beugesehnenverletzungen
US5342612A (en) * 1991-12-20 1994-08-30 American Cyanamid Company Compositions for the treatment of mammalian diseases
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5382435A (en) * 1993-03-24 1995-01-17 Southwest Research Institute Microparticulate pharmaceutical delivery system
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5559110A (en) * 1994-03-09 1996-09-24 The Dupont Merck Pharmaceutical Company Pharmaceutical formulations of cyclic urea type compounds
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
UA41946C2 (uk) * 1994-07-08 2001-10-15 Астра Актієболаг Оральна фармацевтична складова одинична дозована форма у вигляді таблетки, спосіб її одержання, упаковка у вигляді блістера та спосіб інгібування секреції шлункової кислоти і/або лікування шлунково-кишкових запальних захворювань
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
EP1154761B1 (fr) * 1999-02-22 2008-02-20 Merrion Research I Limited Dose orale solide contenant un agent de potentialisation
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
AU2001267011B2 (en) 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
US6248360B1 (en) 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
JP4812225B2 (ja) * 2000-07-11 2011-11-09 塩野義製薬株式会社 生理活性ペプチド含有腸溶性製剤
CA2447444A1 (fr) * 2001-05-11 2002-11-21 Orasense, Ltd. Renforcateurs de permeation antisens
JP2004529953A (ja) * 2001-05-11 2004-09-30 エラン コーポレーシヨン ピーエルシー 浸透促進剤としてのイソステアリン酸塩
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
WO2003090717A1 (fr) * 2002-04-23 2003-11-06 Nanotherapeutics, Inc Procede de formation et de modification de particules et compositions produites au moyen de ce procede
TWI355276B (en) * 2003-01-14 2012-01-01 Akira Tsuji Gastrointestinal absorption enhancer mediated by p
US20050152969A1 (en) * 2004-01-08 2005-07-14 Chiprich Timothy B. Colored liquid-filled soft capsules and method of manufacture thereof
EP1877041A2 (fr) * 2005-04-29 2008-01-16 Cubist Pharmaceuticals, Inc. Compositions therapeutiques
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
JP2009539862A (ja) * 2006-06-09 2009-11-19 メリオン リサーチ Ｉｉｉ リミテッド 強化剤を含む固体経口投与剤形
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
JP2010537989A (ja) * 2007-09-03 2010-12-09 ナノセラピューティクス・インコーポレイテッド 難溶性薬物の組成物及び送達方法
US20100222311A1 (en) * 2007-10-19 2010-09-02 Purdue Research Foundation Solid formulations of crystalline compounds
CA2723541A1 (fr) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions de peptides et leurs procedes de preparation
WO2010099255A1 (fr) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition contenant un bisphosphonate et administration d'un médicament à base de bisphosphonate
CA2784120A1 (fr) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions et procedes d'administration de medicaments par voie orale
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
KR20140026354A (ko) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
WO2013052010A1 (fr) * 2011-10-03 2013-04-11 Agency For Science, Technology And Research Composition antibiotique et ses utilisations
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
WO2019036770A1 (fr) * 2017-08-24 2019-02-28 University Of South Australia Compositions antimicrobiennes et procédés d'utilisation

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE567598A (fr) *
US2476351A (en) * 1945-06-07 1949-07-19 Parke Davis & Co Injectable penicillin compositions
US2487336A (en) * 1946-02-25 1949-11-08 William E Hinds Penicillin product
US2443778A (en) * 1947-04-21 1948-06-22 Monroe J Romansky Preparations for penicillin therapy
US2566200A (en) * 1947-06-07 1951-08-28 Commercial Solvents Corp Oral therapeutic tablets
US2507193A (en) * 1949-05-17 1950-05-09 Bristol Lab Inc Penicillin product
US2805977A (en) * 1955-01-04 1957-09-10 Smith Kline French Lab Sustained release pharmaceutical preparation
US2902407A (en) * 1955-06-14 1959-09-01 Commercial Solvents Corp Wax-coated penicillin product
US2864744A (en) * 1955-09-02 1958-12-16 American Home Prod Penicillin in solid dosage unit form
US3016330A (en) * 1955-11-10 1962-01-09 Novo Terapeutisk Labor As Therapeutical antibiotic composition
US2951014A (en) * 1957-01-03 1960-08-30 Upjohn Co Process for a stable oil suspension
US3402240A (en) * 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
NL297631A (fr) * 1963-06-03
US3849569A (en) * 1965-12-02 1974-11-19 Glaxo Lab Ltd Composition containing procaine penicillin
GB1226555A (fr) * 1967-08-08 1971-03-31
US3549746A (en) * 1967-11-02 1970-12-22 Bristol Myers Co Antibiotic composition
US3626056A (en) * 1967-11-02 1971-12-07 Bristol Myers Co Oral antibiotic product
US3538215A (en) * 1969-06-13 1970-11-03 Allied Chem Stabilized antibiotic in liquid ruminant feed supplement
GB1312918A (en) * 1969-07-08 1973-04-11 Beecham Group Ltd Veterinary treatment
US3696189A (en) * 1970-05-18 1972-10-03 Frank M Snyder Stabilized antibiotic and method
US3655864A (en) * 1970-09-21 1972-04-11 Smith Kline French Lab Glyceryl tristerate and higher fatty acid mixture for improving digestive absorption
JPS4971127A (fr) * 1972-11-18 1974-07-10
GB1413186A (en) * 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
US4145429A (en) * 1974-09-21 1979-03-20 Beecham Group Limited Oral veterinary preparations
US3996355A (en) * 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
GB1547164A (en) * 1975-08-14 1979-06-06 Beecham Group Ltd Veterinary compositions
JPS5231981A (en) * 1975-08-18 1977-03-10 Takeda Chem Ind Ltd Microcapsule preparation method
JPS5283924A (en) * 1976-01-01 1977-07-13 Sumitomo Chem Co Ltd Preparation of pharmaceuticals for rectal infusion containing penicill ins and cephalosporins
JPS6055486B2 (ja) * 1976-02-28 1985-12-05 富山化学工業株式会社 β−ラクタム環を有する化合物の直腸投与用組成物
JPS52139713A (en) * 1976-05-13 1977-11-21 Shionogi & Co Ltd Sustained release cefalexin preparations
DE2654844A1 (de) * 1976-12-03 1978-06-08 Kali Chemie Pharma Gmbh Verfahren zur herstellung fester loesungen von arzneistoffen zur oralen und rektalen applikation
US4250166A (en) * 1977-05-27 1981-02-10 Shionogi & Co., Ltd. Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
SE445174B (sv) * 1978-03-07 1986-06-09 Sandoz Ag Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
IL58462A0 (en) * 1978-10-27 1980-01-31 Beecham Group Ltd Intramammary compositions comprising a penicillin
GB2051574B (en) * 1979-05-10 1984-01-18 Kyoto Pharma Ind Adjuvant for promoting absorption of pharmacologically active substances through the rectum
JPS56104812A (en) * 1980-01-23 1981-08-20 Sankyo Co Ltd Production of cephalosporin compound preparation for rectal infusion
JPS5799519A (en) * 1980-12-12 1982-06-21 Toyo Jozo Co Ltd Stable suppository and its preparation

Also Published As

Publication number Publication date
DK473183A (da) 1984-04-16
NO833757L (no) 1984-04-16
ZA837307B (en) 1984-06-27
AU2019283A (en) 1984-04-19
FI833728A0 (fi) 1983-10-13
ZW22183A1 (en) 1985-04-17
IL69960A0 (en) 1984-01-31
JPS59104312A (ja) 1984-06-16
EP0108295A1 (fr) 1984-05-16
KR840006437A (ko) 1984-11-30
FI833728A (fi) 1984-04-16
US4525339A (en) 1985-06-25
DK473183D0 (da) 1983-10-13
PT77503A (en) 1983-11-01
GR82301B (fr) 1984-12-13

Similar Documents

Publication Publication Date Title
MC1550A1 (fr) Forme de dosage orale
IT1159561B (it) Manipolo dentistico
OA07621A (fr) Forme orale de clométacine et sa préparation.
FI833579A (fi) Eld-retarderande silikonaemnen foer plaster
IT8648450A0 (it) Composizione orale antitartaro
IT1159558B (it) Manipolo dentistico
NO831186L (no) Fortilsetning for droevtyggere
IT1159560B (it) Manipolo dentistico
IT1162879B (it) Composizioni farmaceutiche
IT1159559B (it) Manipolo dentistico
IT8747797A0 (it) Composizione orale antiplacca
BR8307281A (pt) Derivados de pirazolina
DK88383D0 (da) Praeparat pa depotform
DK366083A (da) Uklar tandpasta
DE3371906D1 (de) Deazapurine derivatives
DE3688182D1 (de) Orale zusammensetzung.
AT376561B (de) Zahntechnischer artikulator
BR8304756A (pt) Conversao de gesso
FI831687L (fi) Farmaceutiska blandningar vilka innehaoller flere aktiva bestaondsdelar
ES525621A0 (es) Aparato de impresion
DK133283D0 (da) Doseringsapparat
DOP1983004180A (es) Derivados de acridanona
ES535909A0 (es) Procedimiento de preparacion de derivados de piperacina
SE8300828L (sv) Avtryckssked for dentala endamal
IT8647748A0 (it) Composizione orale antitartaro

Legal Events

Date Code Title Description
YP Annual fee paid